NASDAQ: RXSTRxsight Inc Stock
$8.96-0.12 (-1.32%)
Updated Sep 17, 2025
RXST Price
$8.96
Fair Value Price
N/A
Market Cap
$364.11M
52 Week Low
$6.32
52 Week High
$56.33
P/E
-13.37x
P/B
1.3x
P/S
6.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$148.31M
Earnings
-$26.55M
Gross Margin
71.9%
Operating Margin
-17.84%
Profit Margin
-17.9%
Debt to Equity
0.12
Operating Cash Flow
-$16M
Beta
1.26
Next Earnings
Nov 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RXST Overview
RxSight Incorporated is an ophthalmic technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery. Its FDA-approved proprietary RxSight Light Adjustable Lens system consists of Light Adjustable Lens (LAL), a Light Delivery Device (LDD) and accessories. It is the first and only commercially available intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. RxSight was incorporated in 1997 and is headquartered in Aliso Viejo, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RXST's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important RXST news, forecast changes, insider trades & much more!
RXST News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RXST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RXST is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RXST is good value based on its book value relative to its share price (1.3x), compared to the US Medical Devices industry average (3.98x)
P/B vs Industry Valuation
RXST is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RXST due diligence checks available for Premium users.
Valuation
RXST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.37x
Industry
30.71x
Market
37.36x
RXST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.3x
Industry
3.98x
RXST is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RXST's financial health
Profit margin
Revenue
$37.9M
Net Income
-$8.2M
Profit Margin
-21.6%
RXST's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RXST's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$313.0M
Liabilities
$33.7M
Debt to equity
0.12
RXST's short-term assets ($288.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RXST's short-term assets ($288.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RXST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.8M
Investing
$20.9M
Financing
-$735.0k
RXST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RXST vs Medical Device Stocks
Rxsight Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.